Dr. Judy Hirst and her expert team at Cambridge University, including first author Hannah Bridges, recently released a preprint describing a major advance in understanding of the molecular mechanism of action of biguanides (click here to link to paper). “These studies utilize an ImmunoMet biguanide as representative of the entire biguanide class and provide additional rationale for the clinical development of novel biguanides as Protein Complex 1 inhibitors”, said Dr. Michael Pollak Alexander-Goldfarb Research Chair in Medicinal Oncology at McGill University, and a co-author of the paper. “Metformin is the best known biguanide and widely used in the treatment of type 2 diabetes but novel biguanides may have indications in additional areas, including oncology.”

“These data represent an exciting breakthrough regarding the molecular effects of biguanides on Protein Complex 1 (PC1) and further support clinical development of ImmunoMet’s biguanides, including IM156, as potential novel anti-cancer therapeutics” said Dr. Welsch, Chief Scientific Officer at ImmunoMet Therapeutics. “Furthermore, this study highlights unique differentiation between biguanides and other chemical classes targeting PC1, suggesting the opportunity for the development of additional compounds in our biguanide library”.

About IM156
IM156 is a Protein Complex 1 (PC1) inhibitor that targets the oxidative phosphorylation (OXPHOS) pathway, decreasing the supply of energy and anabolic precursors that are required to drive tumor growth and fibrotic disease. IM156, ImmunoMet’s lead drug candidate, is solely owned by ImmunoMet and is currently in development for the treatment of selected cancers and fibrosis.

About ImmunoMet Therapeutics
ImmunoMet is a clinical stage biotechnology company targeting metabolism for the treatment of cancer and fibrotic diseases. ImmunoMet’s lead molecule, IM156, is a PC1 inhibitor and is the first potent PC1 inhibitor to complete Phase 1 with good tolerability. In addition to IM156, ImmunoMet owns a large library of biguanides with the potential for development, internally or with partners, across multiple indications. The company was founded in 2015 and is headquartered in JLABS @ TMC in Houston. For more information about the company, please visit www.immunomet.com.

Forward-Looking Statements This press release contains “forward-looking statements” concerning the development of ImmunoMet products, the potential benefits and attributes of those products, and the company’s expectations regarding its prospects. Forward-looking statements are subject to risks, assumptions and uncertainties that could cause actual future events or results to differ materially from such statements. These statements are made as of the date of this press release. Actual results may vary. ImmunoMet undertakes no obligation to update any forward-looking statements for any reason.

Company Contacts
Sungwuk Kim
Executive Chairman
swkim@immunomet.com

Michael Bell
Chief Financial Officer
mbell@immunomet.com